Online-Sourced Retatrutide Complicating Impending Diabetic Ketoacidosis in a Patient With Type 1 Diabetes and Concurrent Shigella Gastroenteritis.
Clinicians should be aware of the potential risks associated with unregulated peptides like retatrutide, especially in patients with type 1 diabetes, where management can be complicated by concurrent illnesses.
Where it sits
this study against the rest of the retatrutide (ly3437943) corpusSummary and findings
This case report discusses a man in his mid-30s with type 1 diabetes who experienced severe vomiting, diarrhea, hyperglycemia, and acute kidney injury after self-administering an online-purchased product marketed as retatrutide. Peak ketonaemia reached 4.3 mmol/L, necessitating intravenous insulin and fluid replacement. The report emphasizes the challenges of managing glycemic control in patients with type 1 diabetes exposed to unregulated peptides.
Abstract
Growing public interest in incretin-based therapies for weight loss has been accompanied by increasing availability of research peptides purchasable online. Products may be used without medical assessment or counselling regarding adverse effects, sick-day management or appropriate follow-up. In addition, composition, purity and dosing accuracy may be uncertain. Retatrutide is a novel triple agonist of the glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1 and glucagon receptors currently being investigated for obesity and type 2 diabetes mellitus, but has no established role in type 1 diabetes mellitus. We report a man in his mid-30s with longstanding type 1 diabetes mellitus who presented with severe vomiting, diarrhoea, hyperglycaemia, ketonaemia and acute kidney injury shortly after self-administering an online-purchased product marketed as retatrutide for weight loss. His partner, who had taken the same preparation, also developed gastrointestinal symptoms. Both had also consumed a potential foodborne source of infection. In type 1 diabetes mellitus, where patients remain dependent on exogenous insulin to suppress ketogenesis, gastrointestinal illness may rapidly precipitate ketosis when insulin is omitted and oral intake is reduced. Although diabetic ketoacidosis did not develop, peak ketonaemia reached 4.3 mmol/L in the setting of dehydration and insulin omission, requiring intravenous insulin and fluid replacement. During recovery, recurrent hypoglycaemia required intravenous dextrose and insulin dose adjustment, highlighting challenges of glycaemic management in acutely unwell patients exposed to agents with incretin and glucagon receptor activity. Stool culture subsequently grew Shigella flexneri, introducing diagnostic uncertainty regarding the relative contributions of gastrointestinal infection and retatrutide exposure, and complicating counselling regarding future retatrutide use. While causation cannot be established, the temporal relationship, similar symptoms in another exposed individual, and recognised gastrointestinal adverse-effect profile of retatrutide suggest that exposure may have contributed to symptom severity or amplified the metabolic consequences of infection. This case highlights diagnostic and management challenges created by unregulated research peptides obtained outside healthcare pathways, particularly in patients with type 1 diabetes mellitus where evidence to guide management is limited and clinicians in non-specialist settings may be unfamiliar with these agents. As access expands through online vendors and social media, clinicians should routinely enquire about prescribed and non-prescribed agents when assessing unexplained illness or metabolic decompensation.
Background
This paper addresses the clinical implications of using unregulated peptides like retatrutide in patients with type 1 diabetes. Prior knowledge indicates that incretin-based therapies are primarily investigated for obesity and type 2 diabetes, with limited safety data in type 1 diabetes. The study is significant as it highlights the potential dangers of self-medication with research peptides.
Methods
This is a case report of a man in his mid-30s with longstanding type 1 diabetes. The patient self-administered an online-sourced product marketed as retatrutide. The report details the clinical presentation and management of the patient following exposure.
Results
The patient exhibited severe vomiting, diarrhea, and hyperglycemia, with peak ketonaemia reaching 4.3 mmol/L. The report notes that diabetic ketoacidosis did not develop, but the patient required intravenous insulin and fluid replacement.
Interpretation
The findings suggest a potential link between retatrutide exposure and the severity of symptoms, although causation cannot be definitively established due to confounding factors such as gastrointestinal infection. The effect size, while notable, raises concerns about the clinical significance given the lack of controlled data. This case emphasizes the need for caution in prescribing and using unregulated peptides, particularly in vulnerable populations like those with type 1 diabetes.
Key findings
- Peak ketonaemia reached 4.3 mmol/L.
- Patient presented with severe vomiting, diarrhea, and hyperglycemia.
- Recurrent hypoglycaemia required intravenous dextrose and insulin dose adjustment.
Limitations
- Case report, no control group.
- Causation cannot be established.
- Presence of Shigella complicates findings.
- No long-term follow-up reported.